Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The NKG2A/CD94 receptor complex is a heterodimeric inhibitory immune checkpoint primarily expressed on natural killer (NK) cells and a subset of cytotoxic CD8+ T cells (UniProt P26715, Q13241). It functions by binding to HLA-E (Human Leukocyte Antigen E), a non-classical MHC class I molecule that presents leader sequence peptides from other HLA molecules (PubMed 31213473). In many cancers and viral infections, HLA-E is overexpressed to evade immune surveillance by triggering inhibitory signals through the immunoreceptor tyrosine-based inhibitory motifs (ITIMs) in the NKG2A cytoplasmic tail (PubMed 31213473, 34085431). This interaction effectively suppresses the cytotoxic activity and cytokine production of effector lymphocytes.
Therapeutic agents like monalizumab are designed to block the NKG2A/HLA-E interaction, thereby restoring the anti-tumor and anti-viral functions of the immune system (Innate Pharma, PubMed 30566811). This axis is a key target in modern immunotherapy, often used in combination with PD-1/PD-L1 inhibitors to enhance clinical efficacy in solid tumors and hematological malignancies (PubMed 33139346, 34085431). The blockade of this pathway has shown promise in clinical trials for head and neck squamous cell carcinoma and non-small cell lung cancer, particularly when combined with other checkpoint inhibitors or tumor-targeting antibodies (PubMed 33139346, 34085431).
Immune checkpoint inhibition by blocking the interaction between the inhibitory NKG2A/CD94 receptor on effector cells and its ligand HLA-E on target cells.
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Natural killer cell lectin-like receptor subfamily C member 1 (NKG2A) and Killer cell lectin-like receptor subfamily D member 1 (CD94) complex (NKG2A/CD94).